Public Release: 

Insilico to present the advances in AI for development of aging biomarkers

InSilico Medicine, Inc.


IMAGE: Insilico Medicine presents the advances in biomarker development of human aging at the Artificial Intelligence in Healthcare World Congress 2018. view more 

Credit: Insilico Medicine

Friday, May 4, 2018, Baltimore, MD - Insilico Medicine, a Baltimore-based company specializing in the application of artificial intelligence for drug discovery, biomarker development and aging research, announces the presentation of its CEO, Alex Zhavoronkov, at the World Precision Medicine Congress organized by Terrapinn, May 17, 2018, London, UK.

Dr. Zhavoronkovs's talk "Multi-modal deep learned biomarkers of aging and disease" will cover the latest advances in the application of deep neural networks for the development of robust aging biomarkers. The presentation will also focus on the using of biological age predictors for target identification of age-related diseases and clinical trials enrollment. The presentation will transpire during the "AI in Healthcare" session.

"We are very happy to present our work at the World Precision Medicine Congress, which gathers the key leaders in AI and Healthcare. The topic of aging biomarkers is rapidly gaining popularity and we are happy to be at the leading edge of research and one of the innovation drivers in this area", said Alex Zhavoronkov, PhD, the founder and CEO of Insilico Medicine, Inc.

The World Precision Medicine Congress focuses on the precision medicine pipeline, from early discovery and development of personalised drugs and diagnostics, through to research and innovation, implementing precision medicine into clinics and hospitals. AI in Healthcare session brings together more than 100 medicine and artificial intelligence experts to present their research, case studies and work. The event's organizers aim to investigate the capability of AI to revolutionise hospital management, patient monitoring, big data, drug discovery and biomarker development. The conference will be held on May 16-18, 2018.


Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first who applied deep generative adversarial networks (GANs) to the generation of new molecular structures with specified parameters and published seminal papers in Oncotarget and Molecular Pharmaceutics. The paper published in Molecular Pharmaceutics in 2016 demonstrated the proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. A recent paper published in November 2017 described the application of the next-generation AI and blockchain technologies to return the control over personal data back to the individual. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The most recent paper published in Oncotarget presented the roadmap to enhancing radioresistance for space exploration and colonization.

For further information, images or interviews, please contact:

Contact: Qingsong Zhu, PhD

Official Conference Website:

About Insilico Medicine, Inc

Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions.

The company utilizes advances in genomics, big data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI and Aging.AI and operates Chemistry.AI intended to capture the tacit knowledge of medicinal chemists.

Through a partnership with the BitFury Group, the company is working on a range of AI solutions for blockchain to help return the power over life data back to the individual. The company raised venture capital and partnered with Juvenescence Limited, a holding company focused on longevity biotechnology. The company aspires to become the "Bell Labs" for artificial intelligence and associated technologies for healthcare and longevity biotechnology and commercialize its research by forming subsidiaries around the specific technologies and licensing the intellectual property, molecules and data to the biotechnology and pharmaceutical companies. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. Brief company video:

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.